绥美凯漏服该怎么处理？

(Dolutegravir tablets) was initially approved for marketing in the United States in 2014 and is currently the only three-in-one compound drug containing dolutegravir (DTG). Suimeikai (Dolutea Paramid Tablets, Inbec) has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection. On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation Suimeike (dolutea paramilk tablets, Inbec) was officially launched in mainland China. It is the best-selling AIDS drug in the world in the past five years. So, for AIDS patients, how should they deal with missed doses of Suimeikai?

If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

Suimeike (dolute abalamib tablets, Inbec) is indicated for use in adults and adolescents over 12 years of age (weight at least 40 kg) infected with the human immunodeficiency virus (HIV). Check whether the patient carries the HLA-B*5701 allele. If the patient is known to carry the RLA-B*5701 allele, he should not take treatment with products containing abacavir. The treatment effect varies from person to person, and different physiques and medication methods will have an impact on the effectiveness of the drug.

Patients treated with TRIUMEQ should be aware that patients with pre-existing hepatic dysfunction, including those with chronic active hepatitis, may develop hepatic dysfunction with increased frequency during combination antiretroviral therapy and should be monitored according to standard protocols. If in these patients there is evidence of worsening liver disease, withholding or discontinuing treatment should be considered.

Recommended hot articles: /newsDetail/83768.html